Article
Loss and revival of androgen receptor signaling in advanced prostate cancer
8 Jan 2021
Abstract excerpt
Targeting the androgen receptor (AR) signaling axis has been, over decades, the mainstay of prostate cancer therapy. More potent inhibitors of androgen synthesis and antiandrogens have emerged and have been successfully implemented in clinical practice. That said, the stronger inhibition of the AR signaling axis has led in recent years to an increase of prostate cancers that de-differentiate into AR-negative...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
